Early life is now recognized as a critical and non-redundant time period during which the mucosal tissue and immune system are primed and the enteric microbiota is established. Three factors: the enteric microbiota, the mucosal immune system and the epithelial barrier cooperate to establish intestinal host-microbial homeostasis after birth. They also determine the risk to develop prevalent inflammatory, immune-mediated, and metabolic diseases. Maturation of the mucosal immune system and establishment of the enteric microbiota have been extensively studied. In contrast, postnatal evolvement of epithelial cell type heterogeneity and functional specialization and the influence of enteric infection on this process have not been explored. Therefore, the analysis of the cellular heterogeneity of the intestinal epithelium and its functional specialization during healthy postnatal development but also after early life challenge is the primary aim of the EarlyLife project. Chronic inflammatory, immune-mediated, and metabolic diseases account for significant morbidity in the society and contribute to reduced quality of life, labor force, and increased health care costs. Studies during the last decades suggested that host-microbial interaction at mucosal body sites and here in particular the epithelial surface of the gastrointestinal tract represents a key aspect of immune priming that influences the pathogenesis of prevalent human inflammatory, immune-mediated, and metabolic diseases. In addition, infections of the gastrointestinal tract remain a major cause of childhood mortality and morbidity worldwide. The main clinical symptoms are diarrhea, fluid loss and electrolyte disturbance but gastrointestinal infections during infancy have also been associated with indirect consequences such as reduced growth, body weight gain and delayed intellectual development suggesting a lasting influence on mucosal tissue homeostasis. Thus, a better understanding of the developmental and adaptive processes that determine intestinal epithelial cell type heterogeneity and function both during postnatal development in the healthy individual and after transient challenge for example by enteropathogenic microorganisms is expected to provide novel targets for preventive and therapeutic strategies to reduce the societal burden of chronic diseases. EarlyLife employs innovative, multiscale technical approaches and analytical protocols in combination with novel in vivo models to generate the first comprehensive map of postnatal epithelial cell type and subtype differentiation and analyze the impact of early life infection by important human bacterial, viral, and parasitic pathogens. Effects will be functionally studied using epigenetic profiling, microbiota-transfer experiments, stem cell organoid culture, and genetic models. Identified mechanisms will be confirmed using for example human stem cell organoids. As a result, EarlyLife is expected to identify mechanisms of enhanced infection susceptibility of the neonate, decipher the critical and non-redundant influence of the postnatal period for mucosal homeostasis and explain the role of early life imprinting for long term immune-mediated, inflammatory, and metabolic diseases.